Literature DB >> 14660136

Where to for tobacco regulation: time for new approaches?

Jonathan Liberman1.   

Abstract

From a public health perspective, tobacco remains the number one drug problem facing most countries, even countries such as Australia, which has made considerable headway in reducing tobacco use and associated harm. Clearly more needs to be done, but is it the case that more of the same will be sufficient? In this Harm Reduction Digest based in part on a presentation at the 'International Research Symposium Preventing Substance Use, Risky Use and Harm: What is Evidence-Based Policy?' held in Fremantle, Western Australia in February 2003, the author proposes a new regulatory framework through which to further reduce tobacco-related harm. The paper challenges whether the current profit motive is an appropriate driver of the tobacco industry and suggests a new model of tobacco regulation.

Entities:  

Mesh:

Year:  2003        PMID: 14660136     DOI: 10.1080/09595230310001613985

Source DB:  PubMed          Journal:  Drug Alcohol Rev        ISSN: 0959-5236


  4 in total

1.  The future of tobacco regulation: a response to a proposal for fundamental institutional change.

Authors:  Jonathan Liberman
Journal:  Tob Control       Date:  2006-08       Impact factor: 7.552

Review 2.  Transforming the tobacco market: why the supply of cigarettes should be transferred from for-profit corporations to non-profit enterprises with a public health mandate.

Authors:  C Callard; D Thompson; N Collishaw
Journal:  Tob Control       Date:  2005-08       Impact factor: 7.552

3.  The Lebanese Regie state-owned tobacco monopoly: lessons to inform monopoly-focused endgame strategies.

Authors:  Hala Alaouie; J Robert Branston; Michael John Bloomfield
Journal:  BMC Public Health       Date:  2022-08-29       Impact factor: 4.135

Review 4.  The tobacco endgame: a qualitative review and synthesis.

Authors:  Patricia A McDaniel; Elizabeth A Smith; Ruth E Malone
Journal:  Tob Control       Date:  2015-08-28       Impact factor: 7.552

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.